Ku saabsan-kansarka / daaweynta / tijaabooyinka-kiliinikada / cudurka / merkel-cell / daaweynta

Daaweynta Tijaabooyinka Caafimaadka ee Kansarka Unugga Merkel

Tijaabooyinka caafimaad waa daraasado cilmi baaris ah oo dadka ku lug leh. Tijaabooyinka caafimaad ee liiskan waxaa loogu talagalay daaweynta kansarka unugyada ee Merkel. Dhammaan tijaabooyinka ku jira liiska waxaa taageera NCI.

Macluumaadka aasaasiga ah ee NCI ee ku saabsan tijaabooyinka bukaan socodka wuxuu sharxayaa noocyada iyo wejiyada tijaabooyinka iyo sida loo fuliyo. Tijaabooyinka caafimaad waxay eegaan habab cusub oo looga hortago, lagu ogaado, ama lagu daweeyo cudur. Waxaa laga yaabaa inaad rabto inaad ka fikirto kaqeybqaadashada tijaabada caafimaadka. La hadal dhakhtarkaaga si uu kaaga caawiyo go aansashada haddii mid kugu habboon yahay.

Tijaabooyin 1-25 ee 32 1 2 Ku Xiga>

Pembrolizumab Marka loo Barbardhigo Heerka U Kuurgelidda Daryeelka ee Ku Daaweynta Bukaannada Heerka Baadhitaanka Dhammaystiran ee I-III Merkel Kansarka

Marxaladani tijaabinta wajiga III waxay daraaseyneysaa sida wanaagsan ee ay u shaqeyso pembrolizumab marka la barbar dhigo heerka u kuurgalida daryeelka ee daaweynta bukaannada qaba heerka I-III Merkel kansarka unugga oo gebi ahaanba laga saaray qalliin (dib loo soo saaray). Immunotherapy oo leh unugyada unugyada monoclonal, sida pembrolizumab, ayaa laga yaabaa inay ka caawiso habka difaaca jirka inuu weeraro kansarka, wuxuuna faragelin karaa awooda unugyada burooyinka inay koraan oo ay faafaan. Goobta: 286 goobood

Pembrolizumab oo leh ama aan lahayn Daaweynta shucaaca jirka ee Stereotactic ee lagu daaweynayo bukaanka qaba kansarka hormarka ama metastatic Merkel

Tijaabadan wajiga labaad ee la kala soocay ayaa daraasad ku samaynaysa sida ugu wanaagsan ee pembrolizumab leh ama aan lahayn daaweynta shucaaca jirka ee stereotactic ay ugu shaqayso daaweynta bukaanka qaba kansarka unugga ee Merkel oo ku fiday meelo kale oo jidhka ah. Immunotherapy oo leh unugyada unugyada monoclonal, sida pembrolizumab, ayaa laga yaabaa inay ka caawiso habka difaaca jirka inuu weeraro kansarka, wuxuuna faragelin karaa awooda unugyada burooyinka inay koraan oo ay faafaan. Daaweynta shucaaca jirka ee loo yaqaan 'Stereotactic radiation radiation' waxay isticmaashaa qalab gaar ah si loo meeleeyo bukaanka loona gaarsiiyo shucaaca burooyinka leh saxsanaanta sare. Qaabkani wuxuu dili karaa unugyada burooyinka iyadoo qiyaaso yar la qaato mudo gaaban isla markaana waxyeelo yar u geyso unugyada caadiga ah. Ku siinta pembrolizumab daaweynta shucaaca jirka ee stereotactic waxay si fiican uga shaqeyn kartaa daaweynta bukaanada qaba kansarka unugyada ee Merkel.

Goobta: 246 goobood

Daraasad Immuno-therapy ah oo baaritaan ah oo lagu baarayo amniga iyo waxtarka Nivolumab, iyo Nivolumab Isugeynta Daaweynta ee Burooyinka la xiriira Virus

Ujeedada daraasaddan si loo baaro amniga iyo waxtarka nivolumab, iyo daaweynta isku-darka nivolumab, si loo daaweeyo bukaannada qaba burooyinka la xiriira fayraska. Feyrasyada qaarkood ayaa lagu yaqaan inay door ka ciyaaraan sameynta burooyinka iyo koritaanka. Daraasadani waxay baari doontaa saameynta daawooyinka daraasadda, bukaanada leh noocyada burooyinka soo socda: - Cancer Canal Canal-Mar dambe ma diiwaan galiso nooca burooyinka kansarka ilmo galeenka - Epstein Barr Virus (EBV) kansarka caloosha wanaagsan - Mar dambe ma diiwaangelin tan nooca burooyinka - Kansarka Unugyada Kansarka - Kansarka Penile-Mar dambe ma diiwaangeliyo nooca burooyinkaan - Kansarka siilka iyo xubinta taranka-Mar dambe ma diiwaan galinayo nooca burooyinkaan - Kansarka Nasopharyngeal - Mar dambe ma diiwaangelinayo nooca buro - Madaxa iyo Kansarka Qoorta

Goobta: 10 goobood

Daraasadani waxay Qiimeyneysaa KRT-232, Nobel Oral Molecule Inhibitor of MDM2, ee loogu talagalay Daaweynta Bukaannada (p53WT) Merkel Cell Carcinoma Kuwa Ku Fashilmay Kahortagga PD-1 / PD-L1 Immunotherapy

Daraasadani waxay qiimeyneysaa KRT-232, oo ah sheeko-yare yar-yar oo xakameynaya MDM2, oo loogu talagalay daaweynta bukaannada qaba Merkel Cell Carcinoma (MCC) oo ku guuldareystay daaweynta ugu yaraan hal anti-PD-1 ama anti-PD-L1 immunotherapy. Ka-hortagga MDM2 waa qaab cusub oo ficil ah oo ka socda MCC. Daraasadani waa Wajiga 2, Buug-Furan, Daraasad Gacan-keli ah ee KRT-232 ee Bukaannada qaba p53 Wild-Type (p53WT) Merkel Cell Carcinoma

Goobta: 11 goobood

Adjuvant Avelumab oo ku jira Kansarka unugyada ee 'Merkel Cell Cancer'

Marxaladan tijaabada ah ee la kala soocay III waxay daraasad ku samaynaysaa sida wanaagsan ee avelumab ugu shaqeyso daaweynta bukaanada qaba kansarka unugga ee Merkel oo ku faafay qanjidhada qanjidhka isla markaana qalliin lagu sameeyay ama aan lahayn shucaac shucaac ah. Unugyada difaaca jirka ee Monoclonal, sida avelumab, ayaa kicin kara habka difaaca jirka waxayna faragalin ku yeelan karaan awooda unugyada burooyinka inay koraan oo ay faafaan.

Goobta: 10 goobood

QUILT-3.055: Daraasad ku saabsan ALT-803 oo ku jirta Isku-darka PD-1 / PD-L1 Isbaaroolaha Isbitaalka ee Bukaannada qaba Kansarka Sare

Tani waa Wajiga IIb, hal gacan, multicohort, daraasad calaamadeysan oo calaamado badan oo ALT-803 ah oo ay weheliso baaritaanka kontoroolka baaritaanka FDA-ee la ansixiyay ee PD-1 / PD-L1 ee bukaanada qaba kansarka horumarsan ee horumarka sameeyay ka dib jawaabta bilowga ah daaweynta PD-1 / PD-L1 daaweynta xakamaynta kantaroolka. Dhammaan bukaanada waxay heli doonaan daaweynta isku dhafan ee PD-1 / PD-L1 isbaaro xakameynaha oo lagu daray ALT-803 illaa iyo 16 wareegyada. Wareeg kasta waa lix toddobaad muddada. Dhamaan bukaanada waxay heli doonaan ALT-803 hal mar 3dii asbuucba. Bukaanku sidoo kale waxay heli doonaan isla xakameyn xakameeye oo ay heleen intii lagu jiray daweyntoodii hore. Qiimeynta shucaaca ayaa dhici doonta dhamaadka wareeg kasta oo daaweyn ah. Daaweyntu waxay socon doontaa illaa 2 sano, ama ilaa inta bukaanku la kulmayo la xaqiijiyey cudurka horusocodka ama sunta aan la aqbali karin, ka noqoshada oggolaanshaha, ama haddii Baaruhu uu dareemo inaysan dan ugu jirin bukaanka inuu sii wado daaweynta. Bukaannada waxaa loo raaci doonaa horumarka cudurka, daaweynta ka dib, iyo badbaadada illaa 24 bilood ee la soo dhaafay maamulkii ugu horreeyay ee daroogada daraasadda.

Goobta: 9 goobood

Daraasad ku saabsan NKTR-262 ee Isku-darka NKTR-214 iyo NKTR-214 Plus Nivolumab ee Bukaannada qaba Dhibaatooyinka Burooyinka Deegaanka ee Horumarka leh ama Metastatic Solid

Bukaannadu waxay heli doonaan intra-tumoral (IT) NKTR-262 wareegyada daaweynta 3-toddobaad. Inta lagu jiro Qeybta 1 ee kordhinta qiyaasta ee tijaabada, NKTR-262 waxaa lagu dari doonaa maamulka nidaamka bempegaldesleukin. Kadib go'aaminta qiyaasta Wajiga 2 ee lagu taliyey (RP2D) ee NKTR-262, inta udhaxeysa 6 iyo 12 bukaan ayaa laga qori karaa RP2D si loo sii cadeeyo astaanta badbaadada iyo dulqaadashada isku darka NKTR 262 oo lagu daray bempegaldesleukin (doublet) ama NKTR 262 plus bempegaldesleukin oo lagu daro nivolumab (triplet) ee Cohorts A iyo B, siday u kala horreeyaan. Qeybta ballaarinta Qeybta 2, bukaannada waxaa lagu daaweyn doonaa labalaab ama seddexlaab markii ay soo noqnoqdeen / diidanaayeen iyo khadadkii hore ee daaweynta.

Goobta: 14 goobood

Daraasad ku saabsan INCMGA00012 ee Metastatic Merkel Cell Carcinoma (POD1UM-201)

Ujeedada daraasaddan ayaa ah in la qiimeeyo dhaqdhaqaaqa caafimaad iyo badbaadada INCMGA00012 ee kaqeybgalayaasha oo leh heer sare / metastatic Merkel cell carcinoma (MCC).

Goobta: 8 goobood

PEN-221 gudaha Somatostatin Receptor 2 oo muujinaya Kansarro Hormarsan oo ay kujiraan Neuroendocrine iyo Kansarrada Sambabka Yar Yar

Borotokoolka PEN-221-001 waa calaamad furan, waji kaladuwan Wajiga 1 / 2a daraasad lagu qiimeynayo PEN-221 bukaanada qaba SSTR2 oo muujinaya gastroenteropancreatic horumarsan (GEP) ama sambabada ama thymus ama burooyinka kale ee neuroendocrine ama kansarka sanbabada unugyada yar yar ama kansarka unugyada waaweyn ee neuroendocrine carcinoma sambabka.

Goobta: 7 goobood

Daraasad Wajiga 1/2 ah ee Tallaalka Situit ee Tremelimumab iyo IV Durvalumab Plus PolyICLC ee Mawduucyada leh Kansarrada Horukacsan, Cabbiri kara, Kuwa Biopsy

Kani waa summad furan, daraasad wejiyada 1/2 ah oo kala duwan oo ku saabsan CTLA-4 antibody, tremelimumab, iyo PD-L1 antibody, durvalumab (MEDI4736), oo ay weheliso burooyinka microenvironment (TME) modulator polyICLC, a TLR3 agonist, maadooyinka leh kansarrada horumarsan, la cabbiri karo, biopsy-heli karo.

Goobta: 6 goobood

Intratumoral AST-008 oo lagu daray Pembrolizumab ee Bukaannada qaba Burooyinka Soodhawr Adag

Tani waa wajiga 1b / 2, calaamadeynta furan, tijaabooyin badan oo kala duwan oo loogu talagalay in lagu qiimeeyo amniga, dulqaadka, farmasokokinetics, farmashiyeyaasha iyo waxtarka hordhaca ah ee duritaanka AST-008 intratumoral keligiis iyo isku darka xididka xididada dhiigga ee loo yaqaan 'pembrolizumab' ee bukaanka qaba burooyin adag oo sareeya. Wejiga 1b ee tijaabadani waa 3 + 3 qiyaasta daraasadda kor u qaadista qiimeynta sii kordheysa ama heerarka qiyaasta dhexdhexaadka ah ee AST-008 oo lagu siiyay qaddar go'an oo ah pembrolizumab. Wejiga 2 waa koox fidin ah si loo sii qiimeeyo AST-008 oo lagu daro pembrolizumab oo ku nool dad gaar ah si loo siiyo qiyaas hordhac ah oo ku saabsan waxtarka bukaannada horay u helay oo aan ka jawaabin anti-PD-1 ama anti-PD-L1 antibody daaweynta.

Goobta: 7 goobood

Tijaabinta Cirbadaha Intratumoral Cirbadaha ee TTI-621 ee Mawduucyada Dib-u-soo-Noqoshada iyo Burooyinka Adag ee Soo Noqday iyo Fungoides Mycosis

Tani waa xarumo badan, calaamade furan, waji 1 daraasad loo sameeyay si loo tijaabiyo cirbadaha intratumoral irbadaha ee TTI-621 maadooyinka dib u soo noqoshada iyo diidmada si ula kac ah u soo baxa burooyinka adag ama mycosis fungoides. Daraasadda waxaa lagu samayn doonaa laba qaybood oo kala duwan. Qaybta 1 waa wajiga Kordhinta Qiyaasta iyo Qaybta 2 waa wajiga Ballaarinta Qiyaasta. Ujeedada daraasaddan ayaa ah in lagu tilmaamo astaanta badbaadada ee TTI-621 iyo in la go'aamiyo qiyaasta ugu habboon iyo jadwalka bixinta ee TTI-621. Intaa waxaa dheer, amniga iyo waxqabadka antitumor-ka ee TTI-621 ayaa lagu qiimeyn doonaa iyada oo lagu darayo wakiilo kale oo ka hortaga kansarka ama shucaaca.

Goobta: 5 goobood

Daraasadda RP1 Monotherapy iyo RP1 ee Isku-darka Nivolumab

RPL-001-16 waa Wajiga 1/2, calaamadda furan, xaddiga kordhinta iyo ballaarinta daraasadda bukaan-socodka ee RP1 oo keliya iyo isku-darka nivolumab ee maaddooyinka qaangaarka ah ee leh burooyin heer sare ah iyo / ama diidan, si loo go'aamiyo qiyaasta ugu badan ee loo dulqaadan karo (MTD) iyo lagula taliyay qiyaasta Wajiga 2 (RP2D), iyo sidoo kale in la qiimeeyo waxtarka hordhaca ah.

Goobta: 6 goobood

Talimogene Laherparepvec oo leh ama aan lahayn Daaweynta Shucaaca ee Hypofractionated ee Daaweynta Bukaannada qaba Melanoma Metastatic, Merkel Cell Carcinoma, ama Burooyin kale oo Adag

Tijaabadan wejiga II ah ee la kala soocay ayaa daraasad ku samaynaysa dhibaatooyinka soo raaca ee talimogene laherparepvec iyo in la arko sida wanaagsan ee ay ula shaqayso ama aan loo daaweyn shucaaca hypofractionated ee lagu daaweynayo bukaanka qaba melanoma maqaarka, carcinoma cell cell, ama burooyinka kale ee adag ee ku faafay meelaha aan ku habboonayn in laga saaro qalliinka . Daawooyinka loo isticmaalo habka difaaca jirka, sida talimogene laherparepvec, ayaa kicin kara habka difaaca jirka si loola dagaallamo unugyada burooyinka. Daaweynta shucaaca ee 'Hypofractionated radiation therapy' waxay ku bixisaa qiyaaso badan ee daaweynta shucaaca waqti gaaban waxaana laga yaabaa inay disho unugyo badan oo buro ah ayna yeeshaan waxyeellooyin yar. Weli lama oga haddii la siinayo talimogene laherparepvec oo leh ama aan lahayn daaweynta shucaaca ee loo yaqaan 'hypofractionated radiation therapy' ayaa si fiican uga shaqeyn doonta daaweynta bukaanada leh melanoma maqaarka, carcinoma cell cell, ama burooyinka adag.

Goobta: 3 goobood

FT500 oo ah Daaweynta Daaweynta Daaweynta Daaweynta Daaweynta Daaweynta Daaweynta Cudurka Dabeecadda ee Xakamaynta Mawduucyada leh Burooyin Adag oo Adag

FT500 waa shey-ka-baxsan, waxsoosaarka NK cell-ka ee ka soo jeeda iPSC oo soo koobi kara xasaanadda dabiiciga iyo la-qabsiga, wuxuuna leeyahay awood uu kaga guuleysto farsamooyin badan oo iska caabbinta difaaca jirka ee isbaarada (ICI). Xogta horudhaca ah waxay bixisaa caddayn adag oo taageeraya baaritaanka caafimaad ee FT500 sida monotherapy iyo isku dhafka ICI maadooyinka leh burooyinka adag ee sareeya.

Goobta: 3 goobood

Tacrolimus, Nivolumab, iyo Ipilimumab oo lagu daaweynayo dadka qaata kelyaha ee loo yaqaan 'Kidney Transplant Recipients' iyadoo la xushay Kansarro aan Xanibanayn ama Metastatic

Wejigan I tijaabinta daraasadda sida wanaagsan ee tacrolimus, nivolumab, iyo ipilimumab ay uga shaqeeyaan daaweynta daaweynta qaabilaada kelyaha ee kansarka aan laga saari karin qalliinka (aan la xakamayn karin) ama ku faafay meelo kale oo jidhka ah (metastatic). Tacrolimus waxaa laga yaabaa inay joojiso koritaanka unugyada burooyinka iyagoo xayiraya qaar ka mid ah enzymes-ka loo baahan yahay koritaanka unugyada. Immunotherapy oo leh unugyada unugyada monoclonal, sida nivolumab iyo ipilimumab, ayaa ka caawin kara habka difaaca jirka inuu weeraro kansarka, wuxuuna faragalin ku yeelan karaa awooda unugyada burooyinka inay koraan oo ay faafaan. Bixinta tacrolimus, nivolumab, iyo ipilimumab ayaa si fiican uga shaqeyn kara daaweynta dadka qaata kelyaha ee kansarka marka la barbar dhigo daaweynta kiimikada, qalliinka, daaweynta shucaaca, ama daweynta la beegsanayo.

Goobta: 2 goobood

Nivolumab iyo Ipilimumab oo leh ama aan lahayn Daaweynta shucaaca jirka ee Stereotactic ee lagu daaweynayo bukaanada qaba soo noqnoqda ama marxaladda IV Merkel Kansarka

Tijaabadan wajiga labaad ee la kala soocay ayaa daraasad ku samaynaysa sida wanaagsan ee nivolumab iyo ipilimumab oo leh ama aan lahayn daaweynta shucaaca jirka ee stereotactic daaweynta bukaanka qaba kansarka unugga Merkel ee soo noqday ama heerka IV ah. Immunotherapy oo leh unugyada unugyada monoclonal, sida nivolumab iyo ipilimumab, ayaa ka caawin kara habka difaaca jirka inuu weeraro kansarka, wuxuuna faragalin ku yeelan karaa awooda unugyada burooyinka inay koraan oo ay faafaan. Daaweynta shucaaca jirka ee loo yaqaan 'Stereotactic radiation radiation' waxay isticmaashaa qalab gaar ah si loo meeleeyo bukaanka loona gaarsiiyo shucaaca burooyinka leh saxsanaanta sare. Qaabkani wuxuu dili karaa unugyada burooyinka iyadoo qiyaaso yar la qaato mudo gaaban isla markaana waxyeelo yar u geyso unugyada caadiga ah. Siinta nivolumab iyo ipilimumab oo leh ama aan lahayn daaweynta shucaaca jirka ee stereotactic waxay si fiican uga shaqeyn kartaa daaweynta bukaannada qaba kansarka unugga Merkel.

Goobta: 2 goobood

Pembrolizumab iyo Shucaaca Daaweynta Daaweynta Metastatic Merkel Cell Carcinoma

Tijaabadan wejiga II ah waxay daraasad ku samaynaysaa dhibaatooyinka soo raaca iyo sida wanaagsan ee daaweynta pembrolizumab iyo shucaaca loogu daaweeyo bukaanka qaba kansarka 'cell cell carcinoma' kaasoo ku faafay meelo kale oo jirka ah (metastatic). Immunotherapy oo leh unugyada unugyada monoclonal, sida pembrolizumab, ayaa laga yaabaa inay ka caawiso habka difaaca jirka inuu weeraro kansarka, wuxuuna faragelin karaa awooda unugyada burooyinka inay koraan oo ay faafaan. Daaweynta shucaaca waxay isticmaashaa raajada tamarta sare si loo dilo unugyada burooyinka loona yareeyo burooyinka. Siinta pembrolizumab iyo daaweynta shucaaca waxay kordhin kartaa faa'iidada pembrolizumab.

Goobta: Machadka Kansarka ee Stanford Palo Alto, Palo Alto, California

Daraasad LY3434172, PD-1 iyo PD-L1 Bispecific Antibody, oo kujira Kansarka Hormarsan

Ujeedada ugu weyn ee daraasaddan ayaa ah in la qiimeeyo amniga iyo dulqaadka daroogada daraasadda LY3434172, oo ah antibiyootiko PD-1 / PD-L1, oo ka qaybgalayaasha leh burooyin adag oo horumarsan.

Goobta: Xarunta Kansarka ee MD Anderson, Houston, Texas

Daaweynta Unugyada (Tumor infiltrating Lymphocytes) ee loogu talagalay Daaweynta Cudurrada Gaarka ah ee Deegaanka, Metastatic, ama Soo noqnoqda

Tijaabadan wejiga II ah waxay daraasad ku samaynaysaa sida ugu wanaagsan ee daaweynta unugyada (oo leh burooyinka infakshanka lymfoytesta) ay ugu shaqeyso daaweynta kansarka adag ee ku faafay unugyada u dhow ama qanjidhada (heer sare), ku faafay qaybaha kale ee jirka (metastatic), ama leh soo noqo (soo noqnoqda). Tijaabadani waxay ku lug leedahay ka qaadashada unugyada loo yaqaan 'lymphocytes' (nooc ka mid ah unugyada dhiiga cad) laga soo qaado burooyinka bukaanada, laguna koriyo shaybaarka tiro aad u tiro badan, ka dibna unugyada dib loogu celiyo bukaanka. Unugyadaan waxaa loogu yeeraa burooyinka soo galaya lymphocytes waxaana daaweynta lagu magacaabaa daaweynta unugyada. Bixinta daawooyinka kemotherabi ka hor unugyada ayaa si ku meelgaar ah u xakamayn kara habka difaaca jirka si loo hagaajiyo fursadaha ah in unugyada la dagaalama burooyinka ay awood u yeeshaan inay ku noolaadaan jirka. Bixinta aldesleukin ka dib maamulka unugyada ayaa laga yaabaa inay ka caawiso unugyada la dagaalama burooyinka inay sii noolaadaan waqti dheer.

Goobta: Jaamacadda Pittsburgh Institute Cancer (UPCI), Pittsburgh, Pennsylvania

Nivolumab iyo Shucaaca Daaweynta ama Ipilimumab oo ah Daaweynta Adjuvant ee Daaweynta Bukaannada qaba Kansarka Kansarka ee Merkel

Tijaabadan wejigan 1aad waxay daraasad ku samaysaa dhibaatooyinka soo raaca ah iyo sida wanaagsan ee loo shaqeeyo nivolumab marka la siinayo daaweynta shucaaca ama ipilimumab oo ah daaweyn adjuvant ah oo lagu daaweynayo bukaanada qaba kansarka unugga Merkel. Immunotherapy oo leh unugyada unugyada monoclonal, sida nivolumab iyo ipilimumab, ayaa ka caawin kara habka difaaca jirka inuu weeraro kansarka, wuxuuna faragalin ku yeelan karaa awooda unugyada burooyinka inay koraan oo ay faafaan. Daaweynta shucaaca waxay isticmaashaa raajada tamarta sare leh, gamma rays, neutron, proton ama ilo kale si loo dilo unugyada burooyinka loona yareeyo burooyinka. Ku siinta nivolumab daaweynta shucaaca ama ipilimumab qalliinka kadib waxay dili kartaa unugyada burooyinka ee soo haray.

Goobta: Xarunta Kansarka ee Jaamacadda Ohio State University, Columbus, Ohio

Pembrolizumab (MK-3475) oo ah Daaweynta Koowaad ee loogu talagalay Advanced Merkel Cell Carcinoma (MK-3475-913)

Tani waa hal gacan, calaamad furan, xarumo badan, waxtar leh, iyo daraasad badbaado leh ee pembrolizumab ee kaqeybgalayaasha qaangaarka ah iyo carruurta iyadoo horey aan loo daaweyn Merkel Cell Carcinoma (MCC). Ujeeddada koowaad ee tijaabada waa in la qiimeeyo heerka jawaabta ujeeddada, sida lagu qiimeeyay dib-u-eegis madax-bannaan oo madax-bannaan oo indha sarcaad ah oo ku saabsan Shuruudaha Qiimeynta Jawaab ee Nooca Solid Burooyinka 1.1 (RECIST 1.1) oo wax laga beddelay si loo raaco ugu badnaan 10 dhaawacyo bartilmaameed ah iyo ugu badnaan 5 bartilmaameedyo bartilmaameed xubin kasta, ka dib maamulka pembrolizumab.

Goobta: Xarunta Kansarka ee Laura iyo Isaac Perlmutter oo ku taal NYU Langone, New York, New York

Unugyada unugyada difaaca jirka ee loo yaqaan 'Gene-Modified Immune Cell' (FH-MCVA2TCR) ee lagu daaweynayo bukaanada qaba kansarka unugyada 'Metastatic or Nonsectable Merkel Cancer Cell'.

Tijaabadan wajiga koowaad ee I / II waxay daraasad ku samaynaysaa dhibaatooyinka soo raaca unugyada difaaca jirka ee hiddo-wadaha loo beddelo (FH-MCVA2TCR) iyo in la arko sida wanaagsan ee ay ugu shaqeeyaan daaweynta bukaannada qaba kansarka unugga ee Merkel oo ku faafay qaybaha kale ee jirka (metastatic) ama aan awoodin lagaa saarayo qalliin (lama aqbali karo). Dhigidda hiddo-wadaha lagu abuuray shaybaarka unugyada difaaca jirka waxay horumarin kartaa awoodda jirku u leeyahay inuu la dagaallamo kansarka unugga ee 'Merkel'.

Goobta: Fred Hutch / Jaamacada Washington Dalada Kansarka, Seattle, Washington

Daraasad ku saabsan Amniga iyo dulqaadashada ee INCAGN02390 ee Xullo Xun oo Horumar leh

Ujeedada daraasaddan ayaa ah in la go'aamiyo nabadgelyada, dulqaadka, iyo waxtarka hordhaca ah ee INCAGN02390 ee kaqeybgalayaasha leh xulashooyinka xunxun ee horumarsan.

Goobta: Xarunta Caafimaadka ee Jaamacadda Hackensack, Hackensack, New Jersey

Abexinostat iyo Pembrolizumab ee Daaweynta Bukaannada qaba MSI-Sare ee Deegaanka Sare ama Burooyinka Adag

Tijaabadan wajiga 1aad waxay tijaabineysaa qiyaasta ugu fiican iyo dhibaatooyinka soo raaca ee abexinostat iyo sida wanaagsan ee ay ula shaqeyso iyadoo la siinayo pembrolizumab daaweynta bukaanada leh microsatellite xasiloonida (MSI) burooyinka adag ee ku faafay unugyada u dhow ama qanjidhada qanjirada (heer sare ah) ama meelo kale jirka (metastatic). Abexinostat wuxuu joojin karaa koritaanka unugyada burooyinka isagoo xayiraya qaar ka mid ah enzymes-ka loo baahan yahay koritaanka unugyada. Immunotherapy oo leh unugyada unugyada monoclonal, sida pembrolizumab, ayaa laga yaabaa inay ka caawiso habka difaaca jirka inuu weeraro kansarka, wuxuuna faragelin karaa awooda unugyada burooyinka inay koraan oo ay faafaan. Bixinta abexinostat iyo pembrolizumab ayaa si fiican uga shaqeyn kara daaweynta bukaanada leh burooyinka adag.

Goobta: Xarunta Caafimaadka ee UCSF-Mount Zion, San Francisco, California

1 2 Xiga>